Literature DB >> 11495714

Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing.

J Pereira1, P Lawlor, A Vigano, M Dorgan, E Bruera.   

Abstract

Clinicians involved in the opioid pharmacotherapy of cancer-related pain should be acquainted with a variety of opioids and be skilled in the selection of doses when the type of opioid or route of administration needs changing. The optimal dose should avoid under-dosing or overdosing, both associated with negative outcomes for the patient. Although equianalgesic dose tables are generally used to determine the new doses in these circumstances, the evidence to support the ratios indicated in these tables largely refers to the context of single dose administration. The applicability of these ratios to the setting of chronic opioid administration has been questioned. A systematic search of published literature from 1966 to September 1999 was conducted to critically appraise the emerging evidence on equianalgesic dose ratios derived from studies of chronic opioid administration. There were six major findings: 1) there exists a general paucity of data related to long-term dosing and studies are heterogeneous in nature; 2) the ratios exhibit extremely wide ranges; 3) methadone is more potent than previously appreciated; 4) the ratios related to methadone are highly correlated with the dose of the previous opioid; 5) the ratio may change according to the direction the opioid switch; and 6) discrepancies exist with respect to both oxycodone and fentanyl. Overall, these findings have important clinical implications for clinicians and warrant consideration in the potential revision of current tables. The complexity of the clinical context in which many switches occur must be recognized and also appreciated in the design of future studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495714     DOI: 10.1016/s0885-3924(01)00294-9

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  125 in total

Review 1.  The role and limitations of radiofrequency ablation in treatment of bone and soft tissue tumors.

Authors:  Kamran Ahrar
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

2.  Equianalgesic doses of opioids - their use in clinical practice.

Authors:  Douglas Natusch
Journal:  Br J Pain       Date:  2012-02

3.  Intermittent subcutaneous opioids for the management of cancer pain.

Authors:  Henrique A Parsons; Abdul Shukkoor; Hue Quan; Marvin O Delgado-Guay; J Lynn Palmer; Robin Fainsinger; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-12       Impact factor: 2.947

4.  Methadone initiation and rotation in the outpatient setting for patients with cancer pain.

Authors:  Henrique A Parsons; Maxine de la Cruz; Badi El Osta; Zhijun Li; Bianca Calderon; J Lynn Palmer; Eduardo Bruera
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

Review 5.  Efficacy of Intravenous Lidocaine for Postoperative Analgesia Following Laparoscopic Surgery: A Meta-Analysis.

Authors:  Nicholas T Ventham; Ewan D Kennedy; Richard R Brady; Hugh M Paterson; Doug Speake; Irwin Foo; Kenneth C H Fearon
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

6.  Characteristics of Belgian "life-ending acts without explicit patient request": a large-scale death certificate survey revisited.

Authors:  Kenneth Chambaere; Jan L Bernheim; James Downar; Luc Deliens
Journal:  CMAJ Open       Date:  2014-10-01

7.  Switching from methadone to a different opioid: what is the equianalgesic dose ratio?

Authors:  Paul W Walker; Shana Palla; Be-Lian Pei; Guddi Kaur; Karen Zhang; Jeanine Hanohano; Mark Munsell; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-10       Impact factor: 2.947

8.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

9.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

10.  Opioids switching with transdermal systems in chronic cancer pain.

Authors:  C Aurilio; M C Pace; V Pota; P Sansone; M Barbarisi; E Grella; M B Passavanti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.